-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $5

Benzinga·10/19/2026 16:24:03
Diffusion vocale
Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Neutral and lowers the price target from $7 to $5.